Logo
x

Search

Subscribe Now

EMERGE

The US FDA's Advisory Panel Slams Biogen's Aducanumab for Alzheimer's Disease

The US FDA's Advisory Panel Slams Biogen's Aducanumab for Alzheimer's Disease

  • November 9, 2020
Biogen and Eisai Terminate P-III ENGAGE and EMERGE Study for Alzheimer's Disease

Biogen and Eisai Terminate P-III ENGAGE and EMERGE Study for Alzheimer's Disease

  • March 22, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.